GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy

GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy

YONGIN, South Korea, March 13, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This...

GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC

GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC

YONGIN, South Korea, Jan. 23, 2025 /PRNewswire/ -- GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia. The event was organized in collaboration with...

menu
menu